Firms chase diabetic inflammation with anti-IL-1beta antibodies.
Cormac
C
Sheridan
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy*; D050417:Insulin-Secreting Cells / Q000473:pathology; D053583:Interleukin-1beta / Q000276:immunology*; D010330:Patents as Topic; D014481:United States
D000911:Antibodies, Monoclonal; D053583:Interleukin-1beta